- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Sarepta Therapeutics Reveals Priority Review Voucher Sale in $102M Deal
Company to invest proceeds in further R&D efforts.
Sarepta Therapeutics, a medical research and drug development company, has announced the sale of its rare disease Priority Review Voucher (PRV), receiving $102 upon completion of the sale. According to the company, it plans on using the money earned from the sale towards continued R&D efforts, supporting the development of more transformative therapies.
Following the FDA’s accelerated approval of Elevidys for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD), Sarepta was awarded the PRV. The program is intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
Reference: Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million. Sarepta. July 5, 2023. Accessed July 7, 2023. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-sale-priority-review-voucher-102?_ga=2.38539747.1595629843.1688746964-1480284062.1688746964
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
